Psilocybin / Psilocin

Psychedelicoral · inferred

Tryptamine prodrug found in >200 mushroom species. Rapidly dephosphorylated to psilocin (active 5-HT2A agonist) with a half-life of ~3 hours. Effects last 4-6 hours. Currently in Phase III trials for treatment-resistant depression. Psilocin is further metabolized by MAO and glucuronidation.

Projected serum levels — 3.5 g dried (≈ 35 mg), as needed (shown daily)

Psilocybin / Psilocin (precursor)

Maintenance schedule: 3.5 g dried (≈ 35 mg) as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 8.3 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category: Psychedelic
Route modeled: Oral
Model confidence: inferred
Half-life: 3 h
Common dose: 3.5 g dried (≈ 35 mg)
Reference dose range: 1.8–7 g dried (single dose)
Suggested cadence: as needed (shown daily)
Validated against: 25 mg oral — Cmax 0.019 mg/L at 1.8 h

Documented interactions

danger
1P-LSD (1-Propionyl-LSD) + Psilocybin / Psilocin Serotonin risk
1P-LSD (1-Propionyl-LSD) and Psilocybin / Psilocin both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
25I-NBOMe + Psilocybin / Psilocin Serotonin risk
25I-NBOMe and Psilocybin / Psilocin both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Psilocybin / Psilocin Serotonin risk
2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Psilocybin / Psilocin both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Psilocybin / Psilocin Serotonin risk
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Psilocybin / Psilocin both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
3-MeO-PCP (3-Methoxyphencyclidine) + Psilocybin / Psilocin Serotonin risk
3-MeO-PCP (3-Methoxyphencyclidine) and Psilocybin / Psilocin both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
4-AcO-DMT (Psilacetin) + Psilocybin / Psilocin Stacked effects
4-AcO-DMT (Psilacetin) and Psilocybin / Psilocin both push the serotonin 5HT1A, serotonin 5HT2A, and serotonin 5HT2C in the same direction.

Serum checks 103 modeled interaction pairings for psilocybin / psilocin across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults Brown RT et al. · Clinical Pharmacokinetics, 2017 DOI
Characterized psilocin pharmacokinetics after 0.3 mg/kg oral psilocybin in healthy adults, finding elimination half-life of 3.0 hours with dose-proportional kinetics.
Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants Holze F et al. · Clinical Pharmacology & Therapeutics, 2023 DOI
Comprehensive PK/PD study of 15, 25, and 30 mg oral psilocybin showing psilocin elimination half-lives of 1.4-1.8 hours with maximal concentrations at 2 hours.
In Vitro and In Vivo Metabolism of Psilocybin Active Metabolite Psilocin Rosenbaum JF et al. · Frontiers in Pharmacology, 2024 DOI
Characterized psilocin metabolism pathways including glucuronidation and oxidation by MAO-A, CYP2D6, and CYP3A4 with implications for drug interaction potential.

3 published studies referenced in the app, each with a plain-language summary.